Of Counsel Mark Neuberger was quoted in a Business Insurance article, “Marijuana drug test in works; could be relief for employers,” about the development of a new type of drug test for marijuana use that is set to hit the market next year.
Neuberger, co-chair of Foley’s Cannabis Industry Team, suggested that employers conduct field sobriety tests on employees suspected of marijuana impairment instead of just sending them out for drug testing. “There’s scientific evidence behind that” and it’s legally acceptable, he said. “You don’t need to be a law enforcement person to get training. If you suspect an employee in the workplace is impaired…put them through the test and make a reasonable determination.”
Neuberger, co-chair of Foley’s Cannabis Industry Team, suggested that employers conduct field sobriety tests on employees suspected of marijuana impairment instead of just sending them out for drug testing. “There’s scientific evidence behind that” and it’s legally acceptable, he said. “You don’t need to be a law enforcement person to get training. If you suspect an employee in the workplace is impaired…put them through the test and make a reasonable determination.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”